Tumor necrosis factor related ligand
View Patent ↗Tumor Necrosis Factor Related Ligand (TRELL) polypeptides, a novel member of the tumor necrosis factor family (TNF) and compositions comprising them are disclosed.
1. A substantially pure polypeptide comprising an amino acid sequence that is at least 90% identical to amino acids 139 to 284 of SEQ ID NO:4, wherein the polypeptide is capable of binding to an HT-29 colon carcinoma cell and is cytotoxic to said carcinoma cell.
2. A substantially pure polypeptide comprising an amino acid sequence that is at least 95% identical to amino acids 139 to 284 of SEQ ID NO:4, wherein the polypeptide is capable of binding to an HT-29 colon carcinoma cell and is cytotoxic to said carcinoma cell.
3. The polypeptide of claim 1 , wherein the amino acid sequence is at least 90% identical to amino acids 81 to 284 of SEQ ID NO:4.
4. The polypeptide of claim 2 , wherein the amino acid sequence is at least 95% identical to amino acids 81 to 284 of SEQ ID NO:4.
5. The polypeptide of claim 2 , wherein the amino acid sequence is amino acids 81 to 284 of SEQ ID NO:4 with a single amino acid substitution, deletion or insertion.
6. The polypeptide of claim 2 , wherein the amino acid sequence is amino acids 81 to 284 of SEQ ID NO:4 with one conservative substitution of an amino acid.
7. The polypeptide of claim 1 , wherein the amino acid sequence is at least 90% identical to amino acids 36 to 284 of SEQ ID NO:4.
8. The polypeptide of claim 2 , wherein the amino acid sequence is at least 95% identical to amino acids 36 to 284 of SEQ ID NO:4.
9. A substantially pure polypeptide that comprises amino acids 80 to 225 of SEQ ID NO:2.
10. The polypeptide of claim 9 , wherein the polypeptide comprises amino acids 22 to 225 of SEQ ID NO:2.
11. The polypeptide of claim 10 , wherein the polypeptide consists essentially of amino acids 22 to 225 of SEQ ID NO:2.
12. The polypeptide of claim 11 , wherein the polypeptide consists of amino acids 22 to 225 of SEQ ID NO:2.
13. A substantially pure polypeptide comprising an amino acid sequence at least 90% identical to amino acids 80 to 225 of SEQ ID NO:2, and the polypeptide is capable of binding to an HT-29 colon carcinoma cell and is cytotoxic to said carcinoma cell.
14. The polypeptide of claim 13 , wherein the polypeptide comprises an amino acid sequence that is at least 90% identical to amino acids 22 to 225 of SEQ ID NO:2.
15. A substantially pure polypeptide comprising an amino acid sequence at least 95% identical to amino acids 80 to 225 of SEQ ID NO:2, wherein the polypeptide is capable of binding to an HT-29 colon carcinoma cell and is cytotoxic to said carcinoma cell.
16. The polypeptide of claim 15 , wherein the polypeptide comprises an amino acid sequence at least 95% identical to amino acids 22 to 225 of SEQ ID NO:2.
17. The polypeptide of claim 2 or claim 8 , wherein the polypeptide further comprises an amino acid tag sequence.
18. The polypeptide of claim 2 or claim 8 , wherein the polypeptide comprises a type I or type II leader sequence.
19. A composition comprising the polypeptide according to claim 2 or claim 8 , and a pharmaceutically acceptable carrier.
20. The composition of claim 19 , wherein the composition is formulated for injection.
21. The composition of claim 19 , wherein the composition contains a physiologically compatible buffer.
22. A substantially pure polypeptide comprising an amino acid sequence that is at least 90% identical to amino acids 139 to 284 of SEQ ID NO:4.
23. The polypeptide of claim 22 , wherein the amino acid sequence is at least 90% identical to amino acids 81 to 284 of SEQ ID NO:4.
24. The polypeptide of claim 22 , wherein the amino acid sequence is at least 90% identical to amino acids 36 to 284 of SEQ ID NO:4.
25. A substantially pure polypeptide comprising an amino acid sequence at least 90% identical to amino acids 80 to 225 of SEQ ID NO:2.
26. The polypeptide of claim 25 , wherein the polypeptide comprises an amino acid sequence at least 90% identical to amino acids 80 to 225 of SEQ ID NO:2.
27. The polypeptide of claim 25 , wherein the polypeptide comprises an amino acid sequence at least 90% identical to amino acids 22 to 225 of SEQ ID NO:2.